



Innovating for  
affordable healthcare

## *Shilpa Medicare Limited*

### **Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

Date: 20 May 2024

To  
Corporate Relationship Department  
BSE Limited,  
1<sup>st</sup> Floor, Rotunda Building,  
P.J. Towers, Dalal Street,  
Mumbai – 400 001.

To  
National Stock Exchange of India Limited  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
MUMBAI – 400 051.

Dear Sir/Madam,

**Sub:** Analysts/Investors Call

**Ref:** Scrip Code: BSE - 530549/ Stock Symbol: NSE – SHILPAMED

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q4 & year ended 31 March 2024 Conference Call to be held on Friday, May 24, 2024 at 1:00 PM IST.

Thanking you

**For Shilpa Medicare Limited,**

**Ritu Tiwary**  
**Company Secretary & Compliance Officer**



Innovating for  
affordable healthcare

## Shilpa Medicare Limited's Q4 & FY24 Results Conference call

**Shilpa Medicare Limited** will announce its results for the fourth quarter and financial year ended March 31, 2024 on May 23, 2024. The results & presentation will also be made available on the website of the Company, [www.vbshilpa.com](http://www.vbshilpa.com)

The conference call will be initiated by the senior management with a brief discussion on the Q4 & FY24 results, followed by an interactive Q&A session.

The details of the conference call are:

Date: **May 24, 2024** Time: **1:00 PM IST**

For **Diamond Pass Registration**: [LINK](#)

Local dial-in number	+91 22 6280 1130
	+91 22 7115 8031
International Toll Free Numbers	Hong Kong - 800 964 448
	Singapore - 800 101 2045
	UK - 0 808 101 1573
	USA - 1 866 746 2133

For more information, **visit**: [www.vbshilpa.com](http://www.vbshilpa.com)

For any queries please contact:

<b>Shilpa Medicare:</b> Mr Dilip Kankani Contact: +91 8532 238704 Email: <a href="mailto:dilipkankani@vbshilpa.com">dilipkankani@vbshilpa.com</a>	<b>EY IR :</b> Mr Nachiket Kale Contact: +91 9920 940808 Email: <a href="mailto:nachiket.kale@in.ey.com">nachiket.kale@in.ey.com</a>
--	---

## About Shilpa Medicare Limited:

Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.

Shilpa Medicare has been on path of expansion ever since its inception. With a regulatory recognized manufacturing set up and excellent scientific expert team in place, Shilpa Medicare has since been on a steady growth path. Currently they are one of the leaders in the Oncology market and offer a range of products spanning across APIs, Formulations both in terms of R&D and manufacturing capabilities. Further, to consolidate the overall product offering, they are striving to put in efforts in field of novel drug delivery systems and biotech products along with widening their focus to other therapy areas. Where Shilpa Medicare Ltd is today is the result of their constant endeavours for more than three decades.

## Disclaimer:

*Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward- looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, import duties, litigation, labour relations etc. Actual results might differ substantially from those expressed or implied. Shilpa Medicare Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*